Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00654927
• Other study ID #: MS-F202 EXT
• Status: Completed
• Phase: Phase 3
• First received: April 4, 2008
• Last updated: March 1, 2012
• Start date: November 2003
• Est. completion date: April 2011

Study information

• Verified date: January 2012
• Source: Acorda Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan Corporation sponsored protocol. Subjects are eligible regardless of whether they received active drug or placebo during their participation in the previous study.

Description:

Under the original protocol, patients were to have their treatment dose titrated upwards from a starting dose of 10mg b.i.d. to 15mg b.i.d. and then to a stable (maintenance) dose of 20mg b.i.d. The protocol was subsequently revised to lower the maximum maintenance dose. In the most current protocol, all patients were down-titrated to 10mg b.i.d. and maintained at this dose for the greater part of the duration of the study.

Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. As a result, patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with MS. This study will evaluate the effects and possible risks of taking Fampridine-SR in MS patients over a long period of time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 177
• Est. completion date: April 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• The subject must have been previously enrolled in an Acorda Therapeutics or an Elan Corporation sponsored study for multiple sclerosis and received either Fampridine or placebo.

• The subject must have multiple sclerosis as determined by the Principal Investigator.

• The subject, male or female, must be at least 18 years of age. Any subject who is now over the age of 70 must be in good overall health in the judgment of the Investigator.

• The subject must be of adequate cognitive function, as judged by the Investigator.

• Any subject who is female and of childbearing potential, regardless of sexual activity, must have a negative urine pregnancy test at the Screening Visit.

Exclusion Criteria:

• The subject is a female who is either pregnant or breastfeeding, or of child-bearing potential, who, if engaged in active heterosexual relations and has not had a hysterectomy or bilateral oophorectomy, would not use one of the following birth control methods: tubal ligation, implantable contraception device, oral, injectable or transdermal contraceptive, barrier method or sexual activity restricted to vasectomized partner.

• The subject withdrew from a previous Fampridine study because of a Serious Adverse Event that was possibly, probably or definitely related to Fampridine.

• The subject has a history of seizures or has evidence of past, or possible, epileptiform activity on an EEG.

• The subject has either a clinically significant abnormal ECG or laboratory value(s) at the Screening Visit, as judged by the Investigator

• The subject has angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator.

• The subject has a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine tablet

• The subject has received an investigational drug, except for Fampridine- SR (or matching placebo) under Protocol MS-F202, within 30 days prior to the Screening Visit; or the subject is scheduled to enroll in an investigational drug trial at any time during this study.

• The subject has received compounded 4-aminopyridine (4-AP) within 14 days of the Screening Visit.

• The subject has had an onset of an MS exacerbation within 30 days prior to the Screening Visit, or, if in the judgment of the Investigator, has not stabilized from a prior exacerbation episode.

• The subject has started on a concomitant medication regimen for an underlying disease/symptom within the past 7 days; or has started an interferon or chemotherapeutic agent for multiple sclerosis within the past 4 weeks.

• The subject has a history of drug or alcohol abuse within the past year.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Fampridine-SR b.i.d. (Twice Daily)
Dosage form - tablets.

Locations

Country	Name	City	State
Canada	Foothills Medical Center	Calgary	Alberta
Canada	St. Michael's Hospital	Toronto	Ontario
United States	University of Mexico, MIND Imaging Center	Albuquerque	New Mexico
United States	Shepherd Center	Atlanta	Georgia
United States	Maryland Center for MS	Baltimore	Maryland
United States	Maimonides MS Care Center	Brooklyn	New York
United States	CMC - Neuroscience & Spine Institute, Division of Neurology	Charlotte	North Carolina
United States	University of Chicago	Chicago	Illinois
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	Ohio State University MS Center	Columbus	Ohio
United States	The Schapiro Center for MS	Golden Valley	Minnesota
United States	University of Texas-Houston	Houston	Texas
United States	MS Center at Evergreen	Kirkland	Washington
United States	USC, Keck School of Medicine Health Care Consultation Center	Los Angeles	California
United States	Corinne Goldsmith Dickinson Center for MS	New York	New York
United States	Thomas Jefferson University Physicians	Philadelphia	Pennsylvania
United States	Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center	Phoenix	Arizona
United States	Oregon Health & Science University, MS Center of Oregon, UHS-42	Portland	Oregon
United States	University of Rochester	Rochester	New York
United States	Washington University School of Medicine, Div. of Rehab/Neurology	St. Louis	Missouri
United States	SUNY Stony Brook	Stony Brook	New York
United States	Gimbel MS Center at Holy Name Hospital	Teaneck	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Acorda Therapeutics

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Summary of Treatment Emergent Adverse Events (TEAE).	All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.	over 7 years (2004-2011)	No
Secondary	Timed 25 Foot Walk (T25FW)		Screening visit, visit 4, every 12 weeks thereafter, Last Regular Visit, Follow Up Visit and Early Termination Visit	No
Secondary	Subject Global Impression (SGI)	The patient was asked to complete a Subject Global Impression (SGI) questionnaire at Visit 1 and every study visit thereafter except the Follow-up visit. This questionnaire asked the patient to rate the effects of the investigational drug on his/her physical well-being during the preceding week, using a 1 to 7 point scale (1 = terrible, 7 = delighted)	visit 1 and every clinic visit	No
Secondary	Clinician Global Impression of Change (CGIC)	The CGIC was based on the Investigator's overall impression of the patient's neurological status and general state of health related to his or her participation in the study, specifically in regard to signs and symptoms associated with MS. Neurological status was rated according to a 1 to 7 point scale (1 = very much improved, 7 = very much worse)	visit 1 and every clinic visit	No
Secondary	Expanded Disability Status Scale (EDSS)	Based on the baseline neurological exam, each patient was scored according to the Expanded Disability Status Scale, which rates disability on a 0 to 10 scale (0 = normal neurologic examination, 10 = death); *EDSS assessments were not well synchronized to study period because of wide differences in interval between screening and initiation	Screening visit, visit 6 and every 24 months thereafter	No

External Links

•   (Click here for more information about Fampridine-SR clinical trials)